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Advanced therapeutics, specifically cell and gene therapies, provide an opportunity to target 
previously unmet clinical conditions and offer a potential solution to the social and economic 
burden associated with an aging population [1, 2].  Human mesenchymal stem/stromal cells 
(hMSCs) are a promising cell therapy candidate for the treatment of numerous clinical 
indications [3], however, a transformation is required in the way we isolate, manufacture, 
characterise and deliver these therapies to ensure they are both efficacious and affordable [2, 
4]. Manufacture of hMSCs requires in vitro expansion to increase the available number of cells 
to meet clinical demand, however progress is impeded by the lack of advanced methods for the 
isolation and expansion of cells that are scalable, amenable for automation and closed. 
 
Many allogeneic processes still require manual intervention which has significant quality and 
cost implications [5], and developing reproducible, consistent bioprocesses is still a major 
challenge. Even when a scale-out approach is to be employed (e.g. for autologous therapies), 
there is a significant practical challenge of manipulating, processing and segregating multiple 
production batches in an aseptic, closed manner. Such processes demand small units for 
manufacture in which line segregation is a priority in order to avoid product-patient mismatch 
and disease transmission. As such, there is an industrial trend toward automated systems as it 
is increasingly recognised that such systems facilitate consistent manufacture and will play a 
pivotal role in the translation of cell therapies by improving quality control, process economics, 
scalability, process capability and provide a platform for understanding process variation and 
optimisation [6].   
 
Through AUTOSTEM (European Commission Horizon 2020 funded research and innovation 
actions), academic and industrial groups from across the EU are working in collaboration to 
take a holistic approach to enable large-scale hMSC production, at clinical-grade quality, by 
implementing a robotic automated pipeline for cell isolation and culture [7]. AUTOSTEM 
builds on the ground-breaking work of the StemCellFactory project [8] which built and 
demonstrated an automated robotic pipeline for the production of human induced pluripotent 
cell lines (Figure 1). AUTOSTEM develops this technology further to enable automated, closed 
and Good Manufacturing Practice (GMP)-ready hMSCs (a ‘StromalCellFactory’) and will 
focus on the development of: 
 Medical devices for closed collection of bone marrow and delivery to the pipeline   
 Functionalised culture surfaces with novel proprietary antibodies for specific 
selection of colony-forming fibroblasts (CFU-f)   
 Novel xeno-free bioreactor culture systems and processes using proprietary serum-
free medium  
 In situ mobile sensors for in-line fine process control  
 New tools, automation technologies and software solutions for the integration of 
Multiple bioreactor systems and advanced automated hMSC culture and  
 A novel device to deliver the end-product to the patient. 
 Quality by Design tools to facilitate cost-based and efficient bioprocess 
development 
 
With each cell therapy candidate likely to have a unique bioprocess, the advantage of an 
automated manufacturing system such as this is the ability to develop bespoke, interlinked 
modular units which can be reconfigured and adapted to accommodate new processes or take 
advantage of emerging technologies to facilitate cost and risk based continual process 
improvements [4]. Such systems therefore have the potential to become a true platform 
technology and are amenable to both a centralised and redistributed (decentralised) 
manufacturing model.  Within this specific facility, operator interactions will be limited to 
marrow harvesting and therapeutic cell delivery, and to the operation of the pipeline using 
control software. Specially-adapted metrology and sensors enable real-time online monitoring 
ensuring the automated system is responsive to events and parameters within the pipeline.  
 
A significant challenge in the production of hMSCs is associated with the isolation of the 
optimal cell type. Human MSCs, traditionally isolated by plastic adherence, are a 
heterogeneous population of cells with different levels of stemness. Antibodies associated with 
this property, such as STRO-1, CD271 and CD146, enrich for CFU-f and have variable tissue 
distribution. There is a need to improve and standardise isolation procedures and to this end, 
we will be using newly developed antibody selection methods developed by members of the 
consortium that target the vast majority of CFU-f and have wide tissue and species 
applicability. These will be functionalised to culture surfaces to facilitate the isolation of a more 
homogenous MSC seeding population. This is a key enabler for a more defined therapeutic 
product.  
 
In addition to isolating a more homogenous starting cell population, there are additional factors 
which can significantly impact the bioprocessing and manufacture of stem cell therapies, 
namely the reagents and medium employed [9]. The over-reliance of the cell therapy industry 
on foetal bovine serum (FBS) for large-scale production of clinical grade MSCs is an 
impediment to the development of cell-based regenerative medicine. The 2014 Alliance for 
Regenerative Medicine (ARM) survey of pharmaceutical and large-cap biotechnology 
companies identified “product consistency and lack of standards” as the “single greatest 
challenge facing the field” [10]. In pursuit of a consistent manufacturing process, there is a 
need to identify and minimise any source of variation. As such, there has been a concerted 
effort across the cell therapy and wider biopharmaceutical sector to move towards serum and 
xeno-free medium. Whilst the greatest driver is often safety-oriented with a focus on regulatory 
compliance, there are also significant concerns about batch-to-batch variability associated with 
serum (and the impact this has on the process) and supply and availability of GMP-grade foetal 
bovine serum [1, 11, 12]. It is envisaged that AUTOSTEM’s use of a novel, fully-defined 
growth medium [13], which does not depend on FBS supplies, to culture a defined MSC 
population will enable improved process and product consistency and facilitate the 
development of standard production systems.   
 
Obtaining a sufficient number of hMSCs for a therapy, be it autologous or allogeneic, 
necessitates ex vivo cell culture. Although multiple cell production systems are available [11], 
two of the major cell culture platforms will be considered, a rotating bed bioreactor and 
microcarrier systems used in conjunction with stirred-tank bioreactors. Microcarriers provide 
a significantly larger surface area per unit volume compared to other expansion platforms and 
such systems are scalable, amenable for automation, allow for multiple modes of operation 
(batch, fed-batch, perfusion) and have a significant heritage in biopharmaceutical production 
[1]. Members of this consortium demonstrated the first litre-scale expansion of hMSCs on 
microcarriers in a stirred-tank bioreactor (2.5 L working volume) and developed a scalable 
harvesting technique to obtain single hMSCs without any adverse effect on cell quality [14]. 
The cell density achieved was ~ 1.7 x 105 cells/mL, although recent studies by the group and 
others have demonstrated cell densities approaching clinically-relevant numbers of ~ 1 x 106 
cells/mL [15, 16]. It is likely with further bioprocess development and parameter optimisation, 
cell densities will continue to increase, as has been the case with traditional biopharmaceutical 
development. This, however, potentially brings additional challenges which may not currently 
be problematic such as mass transfer limitations and large aggregate formation and is 
something that requires further investigation should this arise.  
 
Accurate monitoring of process parameters remains a challenge and the available sensing 
technologies tend to be outdated. With the increasing trend in the use of disposable bioreactors 
there is an associated interest in disposable sensors that can be employed within the equipment. 
Current sensors for process monitoring (e.g. PAT sensors in pharmaceutical manufacturing) 
are effective for dO2, pH and temperature (chemical and physical parameters) but less effective 
for key biological parameters such as glucose and lactic acid. They also suffer from coagulation 
and fouling of sensor heads due to the biological nature of the medium and the product [17]. A 
miniaturised sensing device is currently under development that can be housed within the 
bioreactor and continuously monitor the environment.  The sensing device takes the form of a 
free floating probe with a sensing chip and control electronics to control and acquire the data 
that is encased in robust, biocompatible packaging [18]. Cutting edge semiconductor 
fabrication technologies are being applied to develop a multi-parametric sensing chip with the 
potential to monitor key physical, chemical and biological parameters simultaneously in the 
bioreactor environment [19]. These technologies lend themselves to high volume sensor chip 
production which will result in cheap and highly reproducible devices. An electrochemical 
based approach will be applied which allows for micron and nano-scale electrode dimensions 
to be implemented to meet the sensitivity requirements [20].  
 
Manufacturing of advanced therapies requires advanced manufacturing platforms. The 
development of such technologies and processes requires a profoundly multidisciplinary 
approach given the significant overlap between the life science, engineering, clinical and 
commercial interfaces. The underlying problem is a clinical one – to address the shortage and 
availability of advanced therapies. The solution is largely an engineering one – to develop 
scalable bioprocesses and integrate within an automated, modular facility. The understanding 
of the fundamental biology underpins the research focus and the operating context, and the 
focal point for impact, is governed by business and regulatory constraints. Significant 
challenges lie ahead for us, and many other translational researchers in this space, yet the 
emergence of international collaborations between key centres of expertise across multiple yet 
complementary fields to address these challenges bodes well for the cell therapy translational 
landscape. 
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Figure 1. StemCellFactory established for the production of human induced pluripotent 
stem cells. 
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